ERBB2 and cancer: This mechanism of trastuzumab resistance has not been previously identified in HER2-positive gastric cancer model, although recent studies have shown that STAT3 activation promotes epithelial-mesenchymal transition and expansion of cancer stem cells (CSCs) in breast cancer [22-24], which may contribute to trastuzumab resistance.